[Congressional Bills 113th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1429 Introduced in House (IH)]

113th CONGRESS
  1st Session
                                H. R. 1429

    To expand the research and awareness activities of the National 
 Institute of Arthritis and Musculoskeletal and Skin Diseases and the 
Centers for Disease Control and Prevention with respect to scleroderma, 
                        and for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             April 9, 2013

   Mrs. Capps (for herself and Mr. King of New York) introduced the 
   following bill; which was referred to the Committee on Energy and 
                                Commerce

_______________________________________________________________________

                                 A BILL


 
    To expand the research and awareness activities of the National 
 Institute of Arthritis and Musculoskeletal and Skin Diseases and the 
Centers for Disease Control and Prevention with respect to scleroderma, 
                        and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Scleroderma Research and Awareness 
Act of 2013''.

SEC. 2. NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN 
              DISEASES; SCLERODERMA RESEARCH EXPANSION.

    Part B of title IV of the Public Health Service Act (42 U.S.C. 284 
et seq.) is amended by adding at the end the following:

``SEC. 409K. SCLERODERMA RESEARCH.

    ``The Director of NIH may expand, intensify, and coordinate the 
activities of the National Institutes of Health with respect to 
scleroderma, with particular emphasis on the following:
            ``(1) Research focused on the etiology of scleroderma and 
        the development of new treatment options.
            ``(2) Clinical research to evaluate new treatments options.
            ``(3) Basic research on the relationship between 
        scleroderma and secondary conditions such as pulmonary 
        hypertension, gastroparesis, Raynaud's phenomenon, Sjogren's 
        Syndrome, and other diseases as determined by the Director.''.

SEC. 3. PROMOTING PUBLIC AWARENESS OF SCLERODERMA.

    Part P of title III of the Public Health Service Act (42 U.S.C. 
280g et seq.) is amended by adding at the end the following:

``SEC. 399V-6. PROMOTING PUBLIC AWARENESS OF SCLERODERMA.

    ``The Secretary may carry out an educational campaign to increase 
public awareness of scleroderma. Print, video, and Web-based materials 
distributed through this campaign may include--
            ``(1) basic information on scleroderma and its symptoms; 
        and
            ``(2) information on--
                    ``(A) the incidence and prevalence of scleroderma;
                    ``(B) diseases and conditions affiliated with 
                scleroderma; or
                    ``(C) the importance of early diagnosis and 
                treatment of scleroderma.''.
                                 <all>